Basilea Pharmaceutica AG provided earnings guidance for the year 2021. Total revenue, including revenue contributions from Cresemba and Zevtera as well as BARDA reimbursements, offsetting ceftobiprole phase 3 development expenses and other revenue contributions, is expected to amount to approximately CHF 148 million (fiscal year 2020: CHF 127.6 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.3 CHF | +0.12% | -1.10% | +14.16% |
Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.16% | 529M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2021